Th17 cells are abundant in multiple chronic inflammatory and autoimmune diseases. Clinical trials with antibodies to interleukin (IL)-17A, one of the Th17-cell signature cytokines, have recently reported therapeutic benefit in multiple patient populations; however, in Crohn's disease the role of Th17 cells and IL-17A appears to be more complicated. The development of different subsets of Th17 cells and their relative pathogenic activities with a focus on the gut environment will be discussed.
CITATION STYLE
Symons, A., Budelsky, A. L., & Towne, J. E. (2012). Are Th17 cells in the gut pathogenic or protective. Mucosal Immunology. Nature Publishing Group. https://doi.org/10.1038/mi.2011.51
Mendeley helps you to discover research relevant for your work.